Aspira Women’s Health Inc. president and CEO Nicole Sandford tells Proactive’s Stephen Gunnion that the recently-announced co-marketing and distribution collaboration with BioReference, one of the largest full service specialty laboratories in the US, will help broaden access to the company’s Ova1Plus ovarian cancer risk assessment product.
Sandford also discusses the upcoming launch of its next-generation test OvaWatch and the development of endometriosis diagnostic EndoCheck as the bio-analytical based women’s health company targets those affected by gynecologic disease.
#ProactiveInvestors #AspiraWomen’sHealth #BioReference #gynecology #ovariancancer
